RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED AND REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets tough blood cancers in first human trial
Disease control TerminatedThis early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Experimental myeloma drug trial halted early
Disease control TerminatedThis study tested a new drug called CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to check safety, find the best dose, and see if the drug could shrink tumors. Th…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
CAR-T therapy shows promise for Hard-to-Treat myeloma, but trial ends early
Disease control TerminatedThis phase 2 study tested a new CAR-T cell therapy called PHE885 in adults with relapsed and refractory multiple myeloma. The therapy targets a protein called BCMA on myeloma cells. The trial aimed to see how many patients responded, but it was terminated early. Results may still…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC